Please login to the form below

Not currently logged in


This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

Lynparza cleared for first-line ovarian cancer use in China

Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category. AstraZeneca and its marketing partner MSD (known as Merck &Co in North America) have scored marketing authorisation in China for their PARP inhibitor ... Although Lynparza has been the lead in the PARP

Latest news

More from news
Approximately 377 fully matching, plus 1,331 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 9 fully matching, plus 128 partially matching documents found.

Latest appointments

More from appointments
Approximately 37 fully matching, plus 140 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 34 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Language barriers: Obesity has become a loaded word
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....